Association of Renin-Angiotensin-Aldosterone System Inhibitors With Clinical Outcomes, Hemodynamics, and Myocardial Remodeling Among Patients With Advanced Heart Failure on Left Ventricular Assist Device Support

Overview

Journal J Am Heart Assoc

Specialty Cardiology & Vascular Diseases

Date 2024 Apr 30

PMID 38686903

Authors

Guglielmo Gallone

Javier Ibero

Andrew Morley-Smith

Maria Monteagudo Vela

Francesca Fiorelli

Mailen Konicoff

Gemma Edwards

Binu Raj

Mayooran Shanmuganathan

Stefano Pidello

Simone Frea

Gaetano Maria De Ferrari

Vasileios Panoulas

Ulrich Stock

Christopher Bowles

John Dunning

Fernando Riesgo Gil

Affiliations

Soon will be listed here.

Abstract

Background: We evaluated the potential benefits of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with left ventricular assist device support.

Methods And Results: A total of 165 consecutive patients undergoing left ventricular assist device implant and alive at 6-month on support were studied. RAASi status after 6-month visit along with clinical reasons for nonprescription/uptitration were retrospectively assessed. The primary outcome was a composite of heart failure hospitalization or cardiovascular death between 6 and 24 months after left ventricular assist device implant. Remodeling and hemodynamic outcomes were explored by studying the association of RAASi new prescription/uptitration versus unmodified therapy at 6-month visit with the change in echocardiographic parameters and hemodynamics between 6 and 18 months. After the 6-month visit, 76% of patients were on RAASi. Patients' characteristics among those receiving and not receiving RAASi were mostly similar. Of 85 (52%) patients without RAASi new prescription/uptitration at 6-month visit, 62% had no apparent clinical reason. RAASi were independently associated with the primary outcome (adjusted hazard ratio, 0.31 [95% CI, 0.16-0.69]). The baseline rates of optimal echocardiographic profile (neutral interventricular septum, mitral regurgitation less than mild, and aortic valve opening) and hemodynamic profile (cardiac index ≥2.2 L/min per m, wedge pressure <18 mm Hg, and right atrial pressure <12 mm Hg) were similar between groups. At 18 months, patients receiving RAASi new prescription/uptitration at 6 months had higher rates of optimal hemodynamic profile (57.5% versus 37.0%; =0.032) and trends for higher rates of optimal echocardiographic profile (39.6% versus 22.9%; =0.055) compared with patients with 6-month unmodified therapy. Optimal 18-month hemodynamic and echocardiographic profiles were associated with the primary outcome (log-rank=0.022 and log-rank=0.035, respectively).

Conclusions: RAASi are associated with improved outcomes and improved hemodynamics among mechanically unloaded patients.

References

Kanwar M, Selzman C, Ton V, Miera O, Cornwell 3rd W, Antaki J . Clinical myocardial recovery in advanced heart failure with long term left ventricular assist device support. J Heart Lung Transplant. 2022; 41(10):1324-1334. PMC: 10257189. DOI: 10.1016/j.healun.2022.05.015. View

Mann D, Givertz M, Vader J, Starling R, Shah P, McNulty S . Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2021; 7(1):17-25. PMC: 8567189. DOI: 10.1001/jamacardio.2021.4567. View

Qin T, Yao Y . Vasoplegic syndrome in patients undergoing heart transplantation. Front Surg. 2023; 10:1114438. PMC: 9968842. DOI: 10.3389/fsurg.2023.1114438. View

Olsen C, Mandawat A, Sun J, Triana T, Chiswell K, Karra R . Recovery of left ventricular function is associated with improved outcomes in LVAD recipients. J Heart Lung Transplant. 2022; 41(8):1055-1062. DOI: 10.1016/j.healun.2022.03.008. View

Klotz S, Foronjy R, Dickstein M, Gu A, Garrelds I, Danser A . Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation. 2005; 112(3):364-74. DOI: 10.1161/CIRCULATIONAHA.104.515106. View

Drakos S, Mehra M . Clinical myocardial recovery during long-term mechanical support in advanced heart failure: Insights into moving the field forward. J Heart Lung Transplant. 2016; 35(4):413-20. DOI: 10.1016/j.healun.2016.01.001. View

Patel S, Saeed O, Murthy S, Bhatia V, Shin J, Wang D . Combining neurohormonal blockade with continuous-flow left ventricular assist device support for myocardial recovery: a single-arm prospective study. J Heart Lung Transplant. 2013; 32(3):305-12. DOI: 10.1016/j.healun.2012.11.019. View

Pidello S, Frea S, Attisani M, Lodo V, Baronetto A, Savi L . Clinical and Prognostic Role of Noninvasive Hemodynamic Assessment in Left Ventricular Assist Device Carriers. ASAIO J. 2022; 68(11):1367-1371. DOI: 10.1097/MAT.0000000000001682. View

Houston B, Schneider A, Vaishnav J, Cromwell D, Miller P, Faridi K . Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant. 2017; 36(4):380-385. DOI: 10.1016/j.healun.2016.12.016. View

10.

Montalto A, Amarelli C, Piazza V, Hopkins K, Comisso M, Pantanella R . A new hemodynamic index to predict late right failure in patients implanted with last generation centrifugal pump. J Card Surg. 2021; 36(7):2355-2364. DOI: 10.1111/jocs.15564. View

11.

Monteagudo Vela M, Baston V, Panoulas V, Riesgo Gil F, Simon A . A detailed explantation assessment protocol for patients with left ventricular assist devices with myocardial recovery. Interact Cardiovasc Thorac Surg. 2020; 32(2):298-305. PMC: 8906770. DOI: 10.1093/icvts/ivaa259. View

12.

Frea S, Centofanti P, Pidello S, Giordana F, Bovolo V, Baronetto A . Noninvasive Assessment of Hemodynamic Status in HeartWare Left Ventricular Assist Device Patients: Validation of an Echocardiographic Approach. JACC Cardiovasc Imaging. 2018; 12(7 Pt 1):1121-1131. DOI: 10.1016/j.jcmg.2018.01.026. View

13.

Birks E, Drakos S, Patel S, Lowes B, Selzman C, Starling R . Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results. Circulation. 2020; 142(21):2016-2028. DOI: 10.1161/CIRCULATIONAHA.120.046415. View

14.

Catino A, Ferrin P, Wever-Pinzon J, Horne B, Wever-Pinzon O, Kfoury A . Clinical and histopathological effects of heart failure drug therapy in advanced heart failure patients on chronic mechanical circulatory support. Eur J Heart Fail. 2017; 20(1):164-174. DOI: 10.1002/ejhf.1018. View

15.

McCullough M, Caraballo C, Ravindra N, Miller P, Mezzacappa C, Levin A . Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices. JAMA Cardiol. 2019; 5(2):175-182. PMC: 6865330. DOI: 10.1001/jamacardio.2019.4965. View

16.

Dobarro D, Urban M, Booth K, Wrightson N, Castrodeza J, Jungschleger J . Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device. J Heart Lung Transplant. 2016; 36(1):42-49. DOI: 10.1016/j.healun.2016.08.006. View

17.

Nayak A, Hall S, Uriel N, Goldstein D, Cleveland Jr J, Cowger J . Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device. J Am Coll Cardiol. 2023; 82(9):771-781. DOI: 10.1016/j.jacc.2023.05.066. View

18.

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368. View

19.

Klotz S, Danser A, Foronjy R, Oz M, Wang J, Mancini D . The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol. 2007; 49(11):1166-74. DOI: 10.1016/j.jacc.2006.10.071. View

20.

Brinkley Jr D, Wang L, Yu C, Grandin E, Kiernan M . Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report. J Heart Lung Transplant. 2021; 40(12):1605-1613. PMC: 8627474. DOI: 10.1016/j.healun.2021.08.015. View